OncoMatch/Clinical Trials/NCT07284277
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Is NCT07284277 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies TTFields concomitant with modFOLFIRINOX for pancreatic adenocarcinoma metastatic.
Treatment: TTFields concomitant with modFOLFIRINOX — The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: neoadjuvant or adjuvant chemotherapy allowed if at least six months have elapsed since last chemotherapy treatment
Previous treatment with chemotherapy for metastatic pancreatic ductal adenocarcinoma
Cannot have received: radiation therapy
Exception: allowed if completed more than 14 days prior to C1D1 and no persistence of radiation-related adverse effects
Previous radiation therapy within 14 days prior to C1D1 and/or persistence of radiation-related adverse effects
Cannot have received: (brivudine, sorivudine, analogues)
Patients who have received brivudine, sorivudine or analogues 4 weeks prior to Fluoracile administration
Lab requirements
Blood counts
WBC ≥ 2.5 x 10^9/L; ANC ≥ 1.5 x 10^9/L without G-CSF; Platelet count ≥ 100 x 10^9/L without transfusion; Hemoglobin ≥ 9 g/dL (transfusion allowed)
Kidney function
Serum creatinine ≤ 1.5 x ULN or Creatinine Clearance ≥ 30 ml/min (Cockcroft-Gault)
Liver function
Serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease); AST, ALT ≤ 5 x ULN; Albumin ≥ 2.5 g/dL; INR and aPTT ≤ 1.5 x ULN
Adequate hematologic and organ function, defined by the following laboratory test results, obtained during the screening period and before C1D1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07284277 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiation therapy, disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages